In Vitro Osteolytic Activity of Human Myeloma Plasma Cells
Author Information
Author(s): J.-F. Rossil, R. Bataille
Primary Institution: Centre Gui-de-Chauliac, Hôpital Saint-Eloi, Montpellier, France
Hypothesis
Can in vitro osteolytic activity of myeloma plasma cells serve as an indicator of disease severity?
Conclusion
The study found that detectable in vitro bone resorbing activity is associated with active bone disease in myeloma patients.
Supporting Evidence
- Patients with detectable bone resorbing activity had more lytic bone lesions on radiography.
- 100% of patients with significant in vitro bone resorbing activity had an abnormal SCT ACa test.
- A patient with severe hypercalcaemia had significant bone resorbing activity.
- Progression of the disease was observed in 4 out of 6 patients with detectable bone resorbing activity.
Takeaway
Doctors can test myeloma patients' bone activity in the lab to see how serious their disease is.
Methodology
The study involved a radiolabelled bone resorption assay and the salmon calcitonin induced hypocalcaemia test on myeloma patients.
Potential Biases
Potential bias due to the small sample size and the specific patient selection criteria.
Limitations
The study's findings may not apply to all myeloma patients, especially those with indolent disease.
Participant Demographics
Patients were previously untreated with varying degrees of lytic bone lesions.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website